Welcome to our dedicated page for Promis Neuroscie news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on Promis Neuroscie stock.
ProMIS Neurosciences Inc. reports clinical-stage biotechnology developments around antibody therapeutics and vaccines that target toxic misfolded proteins in neurodegenerative diseases. Company news centers on PMN310, its lead humanized monoclonal antibody for Alzheimer’s disease, the PRECISE-AD clinical program, FDA Fast Track designation, biomarker research involving plasma pTau, and scientific publications or conference presentations tied to Alzheimer’s disease, ALS, and Parkinson’s disease.
Updates also cover operating and financial results, governance matters, shareholder votes, capital-structure actions, and investor conference participation. The company’s research disclosures emphasize its proprietary discovery platform and selective targeting of disease-specific toxic protein species rather than broader amyloid plaque binding.
ProMIS Neurosciences (Nasdaq: PMN) reported second quarter 2026 results and a corporate update, highlighted by positive blinded six‑month interim data from PRECISE-AD, its Phase 1b trial of Alzheimer’s candidate PMN310. Among 136 safety‑evaluable patients across all APOE genotypes, there were no ARIA-E cases and a 4.4% rate of mild, asymptomatic ARIA-H, with no treatment-related serious adverse events or drug-related discontinuations.
In the blinded pooled biomarker analysis, plasma pTau217 declined about 15% and CSF MTBR-tau243 about 13.3% from baseline. Cash and short-term investments were $53.4 million at June 30, 2026, up from $6.1 million at year-end 2025, mainly from $70.1 million in January private placement proceeds, funding operations through 2027. Q2 2026 net loss was $11.7 million ($1.28/share) versus $10.1 million ($7.26/share) a year earlier, as R&D and G&A spending increased with pipeline progression.
ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company focused on antibody therapeutics and vaccines for neurodegenerative diseases, will report its second quarter 2026 financial results and provide a business update on August 13, 2026.
The company will host an investor conference call and webcast on August 13, 2026 at 4:30 p.m. Eastern Time. U.S. investors can dial 1-877-407-9208, international participants can dial 1-201-493-6784, using conference ID 13761812. A replay will be available in the Investors section of the ProMIS website.
ProMIS Neurosciences (Nasdaq: PMN) reported positive blinded six‑month interim safety and biomarker data from PRECISE-AD, its Phase 1b trial of PMN310 in 136 Alzheimer’s patients. PMN310 showed a favorable safety profile across all genotypes, with no ARIA-E, 4.4% total ARIA consisting only of mild, asymptomatic ARIA-H, no treatment-related serious adverse events, and no drug-related discontinuations as of the cutoff.
On a blinded basis, 68.5% of patients had declines in plasma pTau217 and 62.5% had declines in CSF MTBR-tau243 versus expected natural-history increases, changes the company links to possible target engagement and the 3:1 randomization, while cautioning these biomarker trends do not establish efficacy. The study has enrolled 144 participants on 5, 10, and 20 mg/kg IV doses for 12 months, with unblinded 12‑month topline results, including efficacy data, expected in Q1 2027.
ProMIS Neurosciences (Nasdaq: PMN) will host a webinar on July 28, 2026, 8:00–9:00 am ET to review upcoming six-month blinded interim data from the PRECISE-AD Phase 1b trial of its lead Alzheimer’s candidate PMN310. Company executives and KOLs Dr. Will Mantyh and Dr. Michael Weiner will discuss aggregate safety findings and trends in select biomarkers in patients with early Alzheimer’s disease.
PRECISE-AD is a randomized, double-blind, placebo-controlled study of multiple ascending intravenous doses (5, 10, 20 mg/kg) of PMN310 over twelve months in 144 enrolled participants. PMN310, a selective anti-amyloid-beta oligomer antibody, received FDA Fast Track designation in July 2025.
ProMIS Neurosciences (Nasdaq: PMN) reported first human evidence that its Alzheimer’s candidate PMN310 achieves dose-dependent reduction of amyloid-beta oligomers (AβO) in cerebrospinal fluid after a single dose in healthy volunteers, using an exploratory ultra-sensitive sFIDA assay, with effects observed at 3 and 29 days.
According to ProMIS Neurosciences, PMN310 showed strict oligomer selectivity, favorable pharmacokinetics with an estimated 27-day CSF half-life, and was generally well-tolerated in Phase 1a. The PRECISE-AD Phase 1b trial in mild cognitive impairment or mild Alzheimer’s has fully enrolled 144 participants and will deliver blinded six-month interim data in the coming weeks and top-line unblinded results in early Q1 2027.
ProMIS Neurosciences (Nasdaq: PMN) will participate in several healthcare and biotech conferences in June 2026, including Jefferies, Wolfe Research’s Virtual Alzheimer’s R&D Day, Oppenheimer CNS Summit, H.C. Wainwright Neuro Perspectives, and BIO International.
CEO Neil Warma will present the EpiSelect™ platform, lead Alzheimer’s candidate PMN310, and timelines for PRECISE-AD Phase 1b data.
ProMIS Neurosciences (Nasdaq: PMN) reported Q1 2026 results and major funding and clinical milestones. The company closed a PIPE financing with potential gross proceeds up to $175 million, including warrant exercises, and held $63.8 million in cash, expected to fund operations through 2027.
The PRECISE-AD Phase 1b trial of PMN310 in Alzheimer’s disease is fully enrolled with 144 participants. A blinded 6‑month safety and biomarker interim analysis is planned for early Q3 2026, with 12‑month unblinded top‑line data anticipated in early 2027.
ProMIS Neurosciences (NASDAQ: PMN) will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026. CEO Neil Warma will present on April 21, 2:30–3:00pm ET and be available for one-on-one investor meetings.
The company said a webcast will be available to registered attendees. ProMIS highlighted progress on its PRECISE-AD Phase 1b trial, targeting a six-month interim blinded safety and biomarker analysis in mid-2026, full dosing by year-end 2026, and anticipated unblinded top-line data in early 2027.
ProMIS Neurosciences (Nasdaq: PMN) reported 2025 results and corporate updates on March 25, 2026, highlighting clinical and financing milestones.
Key points: PRECISE-AD Phase 1b enrollment completed at 144 patients; six-month assessments due Q2 2026 with a blinded interim analysis expected early Q3 2026; top-line data anticipated early 2027. PMN310 shows a favorable safety profile with no treatment-related SAEs to date. The company closed gross up-front financing of $75.5M (part of up to $175M), providing runway through 2027.
ProMIS Neurosciences (Nasdaq: PMN) will present two scientific posters at the AD/PD™ 2026 conference in Copenhagen, March 17–21, 2026. Both posters, scheduled March 20, 2026, describe vaccine and antibody approaches targeting misfolded TDP‑43 and toxic alpha‑synuclein species for ALS and Parkinson’s disease.
Presenters include Neil Cashman and Johanne Kaplan; sessions cover mechanisms, translational strategies, and computationally derived conformational epitopes.